Study of PF-07275315 for moderate to severe COPD
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with COPD for at least 12 months.
- Your lung function tests show moderate to severe airflow limitation (FEV1 between 30% and 70% of normal).
- You have been taking a triple therapy inhaler (LABA, LAMA, and ICS) for at least 6 months, with a stable dose for the last 3 months.
- You have had at least 2 moderate or severe COPD flare-ups in the past year.
- You do not have other major lung diseases like asthma or pulmonary fibrosis.
- You do not have very low blood oxygen levels at rest (SpO2 below 88% on room air) or require high-flow oxygen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests a new medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It is for adults who have had asthma for at least a year, have had recent flare-ups needing steroids, and are not taking other biologic treatments.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests an experimental drug (ExPD-101) given daily as a pill for 52 weeks for people with COPD who have chronic bronchitis and frequent flare-ups. It compares the drug to a placebo (inactive pill) to see if it reduces flare-ups and improves symptoms.
This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.
Hear when a new Moderate to Severe Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.